Peel Hunt restated their hold rating on shares of Vectura Group (LON:VEC) in a report issued on Thursday, ThisIsMoney.Co.Uk reports.
Other equities analysts have also recently issued research reports about the stock. Numis Securities reiterated a buy rating on shares of Vectura Group in a research report on Friday, May 24th. Shore Capital reiterated a hold rating on shares of Vectura Group in a research report on Wednesday, July 17th. JPMorgan Chase & Co. reduced their price target on shares of Vectura Group from GBX 110 ($1.44) to GBX 100 ($1.31) and set an overweight rating on the stock in a research report on Wednesday, April 3rd. Finally, Morgan Stanley reiterated a buy rating and set a GBX 160 ($2.09) price target on shares of Vectura Group in a research report on Friday, May 24th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 130.33 ($1.70).
VEC stock opened at GBX 78.90 ($1.03) on Thursday. Vectura Group has a 1-year low of GBX 65.85 ($0.86) and a 1-year high of GBX 90.15 ($1.18). The company has a current ratio of 2.35, a quick ratio of 1.90 and a debt-to-equity ratio of 0.81. The business’s 50-day simple moving average is GBX 82.30. The company has a market capitalization of $525.71 million and a price-to-earnings ratio of -5.98.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
See Also: S&P 500 Index
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.